- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00236054
A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
May 8, 2014 updated by: Cephalon
A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril (up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD)
Study Overview
Study Type
Interventional
Enrollment
440
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90024
- Pacific Institute For Medical Research, Inc.
-
Newport Beach, California, United States, 92660
- Pharmacology Research Institute
-
San Diego, California, United States, 92108
- Affiliated Research Institute
-
San Diego, California, United States, 92123
- Health Quest Clinical Trials
-
Upland, California, United States, 91786
- Pacific Clinical Research Medical Group
-
-
Florida
-
Jacksonville, Florida, United States, 32257
- UF Behavioral Health Clinic
-
West Palm Beach, Florida, United States, 33407
- Janus Center For Psychiatric Research
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Atlanta Institute of Medicine & Research - Atlanta Clinic
-
-
Illinois
-
Edwardsville, Illinois, United States, 62025
- Cunningham Clinical Research, Llc
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70115
- LSUHSC Anxiety and Mood Disorders Clinic
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48336
- Summit Research Network
-
-
New York
-
Brooklyn, New York, United States, 11235
- Social Psychiatry Research Inst.
-
New York, New York, United States, 10021
- Eastside Comprehensive Medical Center
-
New York, New York, United States, 10023
- Medical and Behavioral Health Research, PC
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
- Hartford Research Group Ltd.
-
-
Oregon
-
Salem, Oregon, United States, 97301
- Oregon Center for Clinical Investigations, Inc.
-
-
South Carolina
-
Charleston, South Carolina, United States, 29407
- South East Health Consultants, LLC
-
-
Washington
-
Bellevue, Washington, United States, 98004
- Northwest Clinical Research Center
-
-
Wisconsin
-
Brown Deer, Wisconsin, United States, 53223
- Northbrooke Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects 18 to 64 years of age (inclusive) will be eligible to participate if they satisfy the DSM-IV-TR criteria for GAD, as well as meeting the required screening and baseline visit scores for a series of psychiatric evaluations (i.e., HAM-A, HADS, MADRS and CGI-S).
Exclusion Criteria:
- Have been previously unresponsive to two or more adequate courses of pharmacological treatment for GAD
- Have been diagnosed with any other psychiatric Axis I disorder (except GAD) as a principal diagnosis within the past six months
- Have been diagnosed with any eating disorder within the past six months
- Have any history of OCD, psychotic disorder, bipolar disorder or antisocial personality disorder
- Have any history of alcohol or substance abuse within the past 3 months
- Have any history of seizures, including febrile seizures
- Have any history of head trauma associated with loss of consciousness within the past 15 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Reduction of symptomatology associated with Generalized Anxiety Disorder as assessed by the change from baseline to endpoint in the total score of the HAM-A scale.
|
Secondary Outcome Measures
Outcome Measure |
---|
Assessment of proportion of responders and
|
patients in remission according to HAM-A scores and CGI ratings by
|
visit, assessment of the safety and tolerability in patients with GAD
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2004
Study Completion
December 1, 2005
Study Registration Dates
First Submitted
October 7, 2005
First Submitted That Met QC Criteria
October 7, 2005
First Posted (ESTIMATE)
October 12, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
May 9, 2014
Last Update Submitted That Met QC Criteria
May 8, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C6671/3032/AX/US
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Anxiety Disorder
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
-
Xijing HospitalRecruitingGeneralized Anxiety DisorderChina
-
Sichuan Jishengtang Pharmaceutical Co., Ltd.Not yet recruitingGeneralized Anxiety Disorder
-
Hospital de Clinicas de Porto AlegreRecruitingGeneralized Anxiety DisorderBrazil
-
University of California, Los AngelesMedical University of South Carolina; Massachusetts General HospitalRecruitingGeneralized Anxiety DisorderUnited States
-
Shahid Beheshti University of Medical SciencesCompletedGeneralized Anxiety DisorderIran, Islamic Republic of
-
Dr. Nazanin AlaviOnline PsychoTherapy ClinicCompletedGeneralized Anxiety DisorderCanada
-
Laureate Institute for Brain Research, Inc.National Institute of Mental Health (NIMH)CompletedGeneralized Anxiety DisorderUnited States
-
The Canadian College of Naturopathic MedicineMassachusetts General Hospital; McGill University; Mitacs; Ekhagastiftelsen; Netherlands... and other collaboratorsActive, not recruitingGeneralized Anxiety DisorderCanada
Clinical Trials on Gabitril
-
CephalonCompletedAnxiety DisorderUnited States, Canada
-
Emory UniversityCephalonCompletedSocial Anxiety DisorderUnited States
-
CephalonCompletedAnxiety DisordersUnited States, Canada
-
CephalonCompletedGeneralized Anxiety DisorderUnited States
-
CephalonCompletedGeneral Anxiety DisorderUnited States
-
Brigham and Women's HospitalCompletedSleep Apnea, ObstructiveUnited States